Nuwellis Enters Agreement with Kluge Design for Aquadex

Nuwellis ( (NUWE) ) has provided an announcement.

On May 9, 2025, Nuwellis, Inc. entered into a Supply & Quality Agreement with Kluge Design, LLC to manufacture and service the Aquadex product line. This agreement, which includes an upfront payment and volume-based payments, involves transferring certain employees to Kluge Design and has an initial term of three years, with automatic renewals. The agreement’s impact includes securing manufacturing capabilities for Nuwellis and ensuring the continuity of their product line, potentially strengthening their position in the medical device industry.

The most recent analyst rating on (NUWE) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.

Spark’s Take on NUWE Stock

According to Spark, TipRanks’ AI Analyst, NUWE is a Neutral.

Nuwellis is facing financial challenges with persistent losses and negative cash flow, impacting its stock score. While recent strategic shifts towards critical care and increased reimbursement rates are promising, the company’s profitability and valuation remain concerns. The technical analysis suggests a bearish trend, and the earnings call highlights both potential and ongoing challenges. Overall, the stock score reflects these mixed factors, with financial performance being the most significant concern.

To see Spark’s full report on NUWE stock, click here.

More about Nuwellis

Nuwellis, Inc. operates in the medical device industry, focusing on products related to fluid management systems. Their primary products include the Aquadex Blood Circuit, Aquadex dELC Catheter, and Aquadex SmartFlow Console, which are designed for fluid removal in patients with fluid overload conditions.

Average Trading Volume: 100,638

Technical Sentiment Signal: Sell

Current Market Cap: $4.32M

For an in-depth examination of NUWE stock, go to TipRanks’ Stock Analysis page.